Pharmacological interventions for hypertension in children
The DOI matches its Crossref record.
Abstract
Background: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data on the long‐term sequelae of persistent hypertension in children, but it is known that children with hypertension have evidence of end organ damage and are at risk of hypertension into adulthood. The prevalence of hypertension in children is rising, most likely due to a concurrent rise in obesity rates. In children with hypertension, non‐pharmacological measures are often recommended as first‐line therapy, but a significant proportion of children will eventually require pharmacological treatment to reduce blood pressure, especially those with evidence of end organ damage at presentation or during follow‐up. A systematic review of the effects of antihypertensive agents in children has not previously been conducted. Objectives: To determine the dose‐related effects of different classes of antihypertensive medications, as monotherapy compared to placebo; as combination therapy compared to placebo or a single medication; or in comparisons of various doses within the same class, on systolic or diastolic blood pressure (or both) in children with hypertension. Search methods: We searched the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 9), Ovid MEDLINE (1946 to October 2013), Ovid EMBASE (1974 to October 2013) and bibliographic citations. Selection criteria: The selection criteria were deliberately broad due to there being few clinical trials in children. We included randomised controlled trials (RCTs) of at least two weeks duration comparing antihypertensive agents either as monotherapy or combination therapy with either placebo or another medication, or comparing different doses of the same medication, in children with hypertension. Hypertension was defined as an average (over a minimum of three readings) systolic or diastolic blood pressure (or both) on the 95thpercentile or above for age, height and gender. Data collection and analysis: Two authors independently selected relevant studies, extracted data and assessed risk of bias. We summarised data, where possible, using a random‐effects model. Formal assessment of heterogeneity was not possible because of insufficient data. Main results: A total of 21 trials evaluated antihypertensive medications of various drug classes in 3454 hypertensive children with periods of follow‐up ranging from three to 24 weeks. There were five RCTs comparing an antihypertensive drug directly with placebo, 12 dose‐finding trials, two trials comparing calcium channel blockers with angiotensin receptor blockers, one trial comparing a centrally acting alpha blocker with a diuretic and one trial comparing an angiotensin‐converting enzyme inhibitor with an angiotensin receptor blocker. No randomised trial was identified that evaluated the effectiveness of antihypertensive medications on target end organ damage. The trials were of variable quality and most were funded by pharmaceutical companies. Among the angiotensin receptor blockers, candesartan (one trial, n = 240), when compared to placebo, reduced systolic blood pressure by 6.50 mmHg (95% confidence interval (CI) −9.44 to −3.56) and diastolic blood pressure by 5.50 mmHg (95% CI −9.62 to −1.38) (low‐quality evidence). High dose telmisartan (one trial, n = 76), when compared to placebo, reduced systolic blood pressure by −8.50 (95% CI −13.79 to −3.21) but not diastolic blood pressure (−4.80, 95% CI −9.50 to 0.10) (low‐quality evidence). Beta blocker (metoprolol, one trial, n = 140), when compared with placebo , significantly reduced systolic blood pressure by 4.20 mmHg (95% CI −8.12 to −0.28) but not diastolic blood pressure (−3.20 mmHg 95% CI −7.12 to 0.72) (low‐quality evidence). Beta blocker/diuretic combination (Bisoprolol/hydrochlorothiazide, one trial, n = 94)when compared with placebo , did not result in a significant reduction in systolic blood pressure (−4.0 mmHg, 95% CI −8.99 to −0.19) but did have an effect on diastolic blood pressure (−4.50 mmHg, 95% CI −8.26 to −0.74) (low‐quality evidence). Calcium channel blocker (extended‐release felodipine,one trial, n = 133) was not effective in reducing systolic blood pressure (−0.62 mmHg, 95% CI −2.97 to 1.73) or diastolic blood pressure (−1.86 mmHg, 95% CI −5.23 to 1.51) when compared with placebo. Further, there was no consistent dose response observed among any of the drug classes. The adverse events associated with the antihypertensive agents were mostly minor and included headaches, dizziness and upper respiratory infections. Authors' conclusions: Overall, there are sparse data informing the use of antihypertensive agents in children, with outcomes reported limited to blood pressure and not end organ damage. The most data are available for candesartan, for which there is low‐quality evidence of a modest lowering effect on blood pressure. We did not find evidence of a consistent dose response relationship for escalating doses of angiotensin receptor blockers, calcium channel blockers or angiotensin‐converting enzyme inhibitors. All agents appear safe, at least in the short term. PLAIN LANGUAGE SUMMARY: Medications for high blood pressure in children Hypertension (high blood pressure) is known to increase the risk of heart disease, stroke and kidney failure. The prevalence of hypertension in children is rising. A significant proportion of children with hypertension require medication to reduce blood pressure and medication use has increased significantly over the past several years. This systematic review includes 21 trials, involving 3454 children, which evaluated different medications to lower blood pressure among children with hypertension. This evidence is up to date as of October 2013. Most trials were of very short duration with the average being seven weeks. The studies were of variable quality and mostly industry funded. Not all studies compared the effect of medication on blood pressure lowering to a placebo. Only a few classes of the commonly prescribed drugs have been evaluated and most had a modest effect on blood pressure, but it is uncertain whether this results in improved long‐term outcomes for children. Higher doses of medication did not result in greater reduction of blood pressure. All of the drugs studied were safe for use, at least in the short term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., et al. (2017) · Pediatrics · doi:10.1542/peds.2017-1904 · Cited by 3,651
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. D. M., Machado, C. A., Poli-de-Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,068
Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Metadata
- Authors
- Chaturvedi, S., Lipszyc, D. H., Licht, C., Craig, J. C., & Parekh, R.
- Venue
- Evidence-Based Child Health: A Cochrane Review Journal
- Publisher
- Wiley
- Published
- 2014-09
- Volume
- 9
- Issue
- 3
- Pages
- 498-580
- ISSN
- 1557-6272 (ISSN-L)
- OpenAlex
- W2024214939
- Cited by
- 41
- References
- 0
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.